1. Home
  2. UCTT vs URGN Comparison

UCTT vs URGN Comparison

Compare UCTT & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ultra Clean Holdings Inc.

UCTT

Ultra Clean Holdings Inc.

HOLD

Current Price

$25.33

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$28.53

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCTT
URGN
Founded
1991
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2004
2017

Fundamental Metrics

Financial Performance
Metric
UCTT
URGN
Price
$25.33
$28.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$32.50
$28.50
AVG Volume (30 Days)
467.0K
1.3M
Earning Date
10-28-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,110,600,000.00
$96,516,000.00
Revenue This Year
N/A
$35.07
Revenue Next Year
$5.74
$117.83
P/E Ratio
N/A
N/A
Revenue Growth
6.65
8.00
52 Week Low
$16.66
$3.42
52 Week High
$40.64
$30.00

Technical Indicators

Market Signals
Indicator
UCTT
URGN
Relative Strength Index (RSI) 50.54 72.41
Support Level $21.49 $24.69
Resistance Level $25.73 $30.00
Average True Range (ATR) 1.25 1.56
MACD 0.26 0.36
Stochastic Oscillator 73.20 79.38

Price Performance

Historical Comparison
UCTT
URGN

About UCTT Ultra Clean Holdings Inc.

Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are Americas, Asia Pacific and EMEA.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: